Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-10
DOI
10.3389/fonc.2022.865350
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
- (2022) J. Matthijs Moll et al. PROSTATE
- ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling
- (2021) Hao Tian et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
- (2021) Michael L. Mohler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.
- (2021) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
- (2021) Eva Estébanez-Perpiñá et al. Cancers
- A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
- (2021) Xuanrong Chen et al. Translational Andrology and Urology
- iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis
- (2021) Jibin Guan et al. ADVANCED FUNCTIONAL MATERIALS
- The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
- (2021) Mark P Labrecque et al. ENDOCRINE-RELATED CANCER
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
- (2021) Linrong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
- (2021) Sylvan C. Baca et al. Nature Communications
- Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
- (2021) Mamta Parikh et al. Scientific Reports
- PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
- (2021) Si-Min Qi et al. Frontiers in Pharmacology
- Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment
- (2021) Jian-Jia Liang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer
- (2021) Claudia Enriquez et al. CANCER RESEARCH
- BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
- (2021) Dae-Hwan Kim et al. CLINICAL CANCER RESEARCH
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular events in neuroendocrine prostate cancer development
- (2021) Yong Wang et al. Nature Reviews Urology
- Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
- (2021) Yuan Liu et al. Cell Death & Disease
- AR Splicing Variants and Resistance to AR Targeting Agents
- (2021) Mayuko Kanayama et al. Cancers
- Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
- (2021) Xiaonan Cong et al. Frontiers in Oncology
- The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance
- (2021) Che-Yuan Hu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
- (2021) Corinne Maurice-Dror et al. INVESTIGATIONAL NEW DRUGS
- The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
- (2021) Neha Singh et al. Nature Communications
- Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
- (2021) Paloma Cejas et al. Nature Communications
- Epigenetic modulations and lineage plasticity in advanced prostate cancer
- (2020) R. Ge et al. ANNALS OF ONCOLOGY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain
- (2020) Shihong Peng et al. CELL BIOLOGY AND TOXICOLOGY
- Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor
- (2020) Marianne D. Sadar Expert Opinion on Drug Discovery
- Targeting RET Kinase in Neuroendocrine Prostate Cancer
- (2020) Halena R VanDeusen et al. MOLECULAR CANCER RESEARCH
- Determining the Drug-Like Properties of Ailanthone, a Novel Chinese Medicine Monomer with Anti-CRPC Activity
- (2020) Pan Hu et al. PLANTA MEDICA
- Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
- (2020) Hendrik Van Poppel et al. INTERNATIONAL JOURNAL OF UROLOGY
- Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
- (2020) Yukiyoshi Hirayama et al. Molecular Oncology
- Nobiletin in Cancer Therapy: How This Plant Derived-Natural Compound Targets Various Oncogene and Onco-Suppressor Pathways
- (2020) Milad Ashrafizadeh et al. Biomedicines
- The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells
- (2020) James E. Melnyk et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader
- (2020) Hang Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2
- (2020) Qiuli Liu et al. JOURNAL OF PATHOLOGY
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases
- (2020) Hang Hu et al. Chemical Biology & Drug Design
- Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
- (2020) Akshay D. Takwale et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC resistant to Second-Line Antiandrogen Therapy
- (2020) Geun Taek Lee et al. MOLECULAR CANCER THERAPEUTICS
- Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer
- (2020) Shidong Lv et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
- (2019) Maria V. Luna Velez et al. ONCOGENE
- Rutaecarpine: A Promising Cardiovascular Protective Alkaloid from Evodia Rutaecarpa (Wu Zhu Yu)
- (2019) Kun-ming Tian et al. PHARMACOLOGICAL RESEARCH
- ONECUT2 is a driver of neuroendocrine prostate cancer
- (2019) Haiyang Guo et al. Nature Communications
- Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
- (2019) Fu-Ju Chou et al. EBioMedicine
- Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
- (2019) Davide Di Fusco et al. Frontiers in Pharmacology
- Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.
- (2019) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression
- (2019) Yinan Li et al. EUROPEAN UROLOGY
- The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
- (2019) Martina Pagliuca et al. DRUGS
- Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer
- (2019) Miguel Reina-Campos et al. CANCER CELL
- Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice
- (2019) Shuowen Tang et al. FITOTERAPIA
- ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
- (2019) Chi-Ping Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Nobiletin and Derivatives: Functional Compounds from Citrus Fruit Peel for Colon Cancer Chemoprevention
- (2019) Goh et al. Cancers
- Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
- (2019) Suriyan Ponnusamy et al. CLINICAL CANCER RESEARCH
- N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
- (2019) Adeline Berger et al. JOURNAL OF CLINICAL INVESTIGATION
- A novel small molecule targets androgen receptor and its splice variants in castration-resistant prostate cancer
- (2019) Zhenyu Yang et al. MOLECULAR CANCER THERAPEUTICS
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
- (2019) Qin Feng et al. Frontiers in Oncology
- The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
- (2019) Alastair Davies et al. ENDOCRINE-RELATED CANCER
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel androgen receptor antagonist JJ‐450 inhibits enzalutamide‐resistant mutant AR F876L nuclear import and function
- (2019) Zeyu Wu et al. PROSTATE
- Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
- (2018) Heini M. L. Kallio et al. BRITISH JOURNAL OF CANCER
- Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
- (2018) Max A. Cheng et al. CANCER LETTERS
- ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3
- (2018) WanYing Lin et al. CANCER LETTERS
- Androgen Receptor–Targeted Treatments for Prostate Cancer: 35 Years’ Progress with Antiandrogens
- (2018) E. David Crawford et al. JOURNAL OF UROLOGY
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies
- (2018) Loredana Puca et al. Cold Spring Harbor Perspectives in Medicine
- ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis
- (2018) Yuanjie Niu et al. CANCER LETTERS
- Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer
- (2018) Lanbo Xiao et al. CANCER RESEARCH
- Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
- (2018) Yan Zhang et al. Nature Communications
- A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network
- (2018) Ahn R. Lee et al. EBioMedicine
- Alternative RNA splicing of the GIT 1 gene is associated with neuroendocrine prostate cancer
- (2018) Ahn R. Lee et al. CANCER SCIENCE
- Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone
- (2017) Khalid Z Masoodi et al. ENDOCRINOLOGY
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer
- (2017) Bin Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.
- (2017) Kush Dalal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
- (2017) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules
- (2017) Khalid Z. Masoodi et al. MOLECULAR CANCER THERAPEUTICS
- Androgen Signaling in Prostate Cancer
- (2017) Charles Dai et al. Cold Spring Harbor Perspectives in Medicine
- A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer
- (2017) Song Liu et al. eLife
- EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
- (2016) Eva De Mol et al. ACS Chemical Biology
- Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells
- (2016) Paul A. Johnston et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L
- (2016) Ronghao Wang et al. CANCER LETTERS
- ASC-J9®, and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals
- (2016) Simeng Wen et al. CANCER LETTERS
- Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
- (2016) Y. C. Yang et al. CLINICAL CANCER RESEARCH
- Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells
- (2016) Simeng Wen et al. MOLECULAR CARCINOGENESIS
- Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
- (2016) Yundong He et al. Nature Communications
- CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy
- (2016) Huiying Sun et al. Hormones & Cancer
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
- (2015) Shinichi Yamashita et al. NEOPLASIA
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells
- (2014) Javid A. Dar et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors
- (2013) Feng Sun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
- (2013) Huifang Li et al. Journal of Chemical Information and Modeling
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
- (2013) Ravi Shashi Nayana Munuganti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Genomics-Guided Discovery of Thailanstatins A, B, and C As Pre-mRNA Splicing Inhibitors and Antiproliferative Agents from Burkholderia thailandensis MSMB43
- (2013) Xiangyang Liu et al. JOURNAL OF NATURAL PRODUCTS
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
- (2012) Kuo-Pao Lai et al. AMERICAN JOURNAL OF PATHOLOGY
- Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice
- (2012) Jun Yang et al. Nanomedicine
- Alternatively spliced androgen receptor variants
- (2011) Scott M Dehm et al. ENDOCRINE-RELATED CANCER
- Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo
- (2011) Justin B. Lee et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
- (2011) Nathan A. Lack et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Adeno-associated virusâdelivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: A preclinical study
- (2009) Aijing Sun et al. INTERNATIONAL JOURNAL OF CANCER
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors
- (2008) R. Snoek et al. CLINICAL CANCER RESEARCH
- Characterization of Nuclear Import of the Domain-Specific Androgen Receptor in Association with the Importin α/β and Ran-Guanosine 5′-Triphosphate Systems
- (2008) Natsuko Kaku et al. ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started